戻る Agenda
Session 4: Risk Management for Opioids: What’s New?
Session Chair(s)
Rania Mouchantaf, PhD
A/Executive Director, Marketed Pharmaceuticals Bureau, MHPD
Health Canada, Canada
The Government of Canada is committed to protecting the health and safety of all Canadians through a comprehensive, compassionate, collaborative and evidence-based approach to addressing problematic substance use. In June 2017, Health Canada proposed amendments to the Food and Drug Regulations that would enable the Minister of Health to require pharmaceutical manufacturers to have in place a risk management plan to monitor and mitigate risks associated with their opioid products, once they are on the market. This session will give an update on the progress of the measures to implement greater Risk Management for Opioids.
Speaker(s)
Risk Management Plans for Opioids in Canada
Andrew Slot, PhD
Health Canada, Canada
Manager
Canadian Databases for Mapping Out Opioid-Related Harms and Evaluating Effectiveness of Risk Minimization Measures
Yola Moride, PhD, FISPE
YolaRX Consultants, Canada
President
The US Approach to Opioids Risk Management: How Can Canada Use These Learnings
Ravi Deshpande, PharmD
McKesson Canada , Canada
Senior Vice President, Specialty Health